RxDoctor Payments Data

Andreas Brieke, MD

Advanced Heart Failure and Transplant Cardiology · Aurora, CONPI 1518057199

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (36.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 77.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $7,872 and has fallen 98.3% since, to $132 in 2025.

$13,811in general payments, 2019–2025

Across 88 payments — averaging $156.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$11K
  • Ancora Heart, Inc.$1K
  • Abiomed$850
  • Edwards Lifesciences$434
  • Medtronic$424
  • Procyrion, Inc.$316
  • plus $11 from 1 others
$244,639in research payments, 2019–2025

Across 83 payments — averaging $2947.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$196K
  • Procyrion, Inc.$32K
  • Edwards Lifesciences$17K

What the payments were for

  • Speaking & faculty fees$3,79327%
  • Travel & lodging$5,02336%
  • Food & beverage$4,99636%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott68$10,686
Ancora Heart, Inc.3$1,091
Abiomed6$850
Edwards Lifesciences2$434
Medtronic5$424
Procyrion, Inc.3$316
Heartflow, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$83,225
Medicare patients
665
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan68$103,750
JardianceEmpagliflozin45$69,650
EliquisApixaban40$51,216
FarxigaDapagliflozin Propanediol44$45,101
Tacrolimus26$10,538
OzempicSemaglutide12$9,616
VerquvoVericiguat13$7,713
Digoxin19$2,605
Eplerenone25$2,120
Mycophenolate Mofetil17$1,576
Metoprolol Succinate101$1,131
Potassium Chloride17$1,000
Ezetimibe16$789
Spironolactone88$741
Carvedilol58$696

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →